BioSpace News Archive

Global Genes and RARE-X, leaders in rare disease patient advocacy and capacity building, announced that their respective boards of directors have signed a definitive agreement to combine the two organizations.

Twist Bioscience Corporation today announced that it has earned Great Place to Work ® Certification™ in the U.S. for the second consecutive year, and for the first time in China, Germany, Singapore, and the United Kingdom.

$97 million investment enhances bioanalytical services, helping pharma and biotech customers accelerate drug development Thermo Fisher Scientific, the world leader in serving science, expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia.

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Company’s board of directors (the “Board”) has approved a reverse stock split of its common stock at a ratio of 1 post-split share for every 50 pre-split shares.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced its management team will participate in an Opening Bell Ceremony at the Nasdaq Stock Market on Thursday, October 13, 2022.

Simulations Plus , Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of version 9.8.3 of its flagship physiologically based biopharmaceutics (PBBM) / pharmacokinetics (PBPK) modeling platform, GastroPlus®.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) shared data from three posters presented during the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting (NASPGHAN) taking place October 12-16, 2022, in Orlando, Florida.

AIM ImmunoTech Inc. announced its Investigational New Drug application filed with the U.S. Food and Drug Administration may proceed to initiate a Phase 2 study evaluating its investigational drug, Ampligen, as a therapeutic for patients with post-COVID conditions.

Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF) announced today its presence at the upcoming 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases (‘‘ADDDS’’) held on November 1-3, 2022, in Boston, MA, USA.

Codex DNA, Inc. today announced a plan to change its Company name to Telesis Bio.